ZOTON

This brand name is authorized in Australia, Estonia, Ireland, Italy, United Kingdom

Active ingredients

The drug ZOTON contains one active pharmaceutical ingredient (API):

1 Lansoprazole UNII 0K5C5T2QPG - LANSOPRAZOLE

Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid. Read about Lansoprazole

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZOTON FASTAB Oro-dispersible tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A02BC03	Lansoprazole	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BC Proton pump inhibitors
Discover more medicines within A02BC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11697P, 12276D, 9331D, 9477T, 9478W
Country: EE	Ravimiamet	Identifier(s): 1621718
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 14167, 40412, 40420
Country: IE	Health Products Regulatory Authority	Identifier(s): 53737, 53753, 53801, 53840, 54025, 54047, 70904, 70951, 70986, 71047, 71061, 71105, 71106
Country: IT	Agenzia del Farmaco	Identifier(s): 028775070, 028775094